No Data
No Data
Hinova Pharmaceuticals Gets US FDA's Nod to Trial HP537 Tablets
Hinova Pharmaceuticals (SHA:688302) obtained approval from the US Food and Drug Administration to conduct clinical trials on the drug HP537 tablets, the company said in its filing on the Shanghai Stoc
Express News | Hinova Pharma Receives U.S. FDA Study May Proceed Notification for Phase I/II Clinical Trial of HP537 for Treatment of Hematological Malignancies
Hai-Chuang Pharmaceutical (688302.SH) received FDA approval for Phase I/II clinical trials of HP537 tablets for the treatment of hematologic malignancies.
Zhitong Finance APP News, Hicreative Pharmaceutical (688302.SH) announced that the company recently received the Study May Proceed Notification issued by the Food and Drug Administration (FDA), approving the company's clinical phase I/II trial application of HP537 tablets for the treatment of hematologic malignancies. Prior to this, the clinical trial application of HP537 tablets in China had been approved by the National Medical Products Administration (NMPA) in February 2024.
Express News | Hinova Pharmaceuticals Receives FDA Fast Track Designation for HP518 for Treatment of Ar+ Triple-Negative Breast Cancer (Tnbc)
Hai-Chuang Pharmaceutical (688302.SH): Its investigational drug HP518 has received Fast Track Designation from the United States Food and Drug Administration for the treatment of androgen receptor (AR)-positive triple-negative breast cancer.
On June 30th, Gelunhui reported that Haichuang Pharmaceutical Co., Ltd. (688302.SH) recently received "Fast Track Designation" ("FTD") from the US Food and Drug Administration ("FDA") for its HP518 tablets for the treatment of androgen receptor (AR) positive triple-negative breast cancer. Currently, there are no similar targeted products approved for marketing at home or abroad. Previously, HP518 tablets have been used in Australia to treat metastatic castration-resistant prostate cancer.
Hinova Pharmaceuticals (SHSE:688302) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring reve
No Data